ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

Acadia Pharmaceuticals (ACAD) stock was in focus Friday after multiple analysts lowered their price targets following topline results from the Phase 2 portion of the RADIANT program evaluating Remlifanserin in Alzheimer's disease psychosis.ACAD shares were down 5% at the time of writing on Friday.A…